Shanghai - Delayed Quote CNY
GemPharmatech Co., Ltd. (688046.SS)
11.37
+0.06
+(0.53%)
At close: 3:00:04 PM GMT+8
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jing Zhao Ph.D. | GM & Director | -- | -- | 1981 |
| Mr. Chongbo Xu CPA, M.B.A. | Chief Financial Officer | -- | -- | 1984 |
| Ms. Zhongyu Li | Deputy GM & Director | -- | -- | 1964 |
| Mr. Tao Wang | Deputy GM & Director | -- | -- | 1985 |
| Mr. Yiou Wang | Board Secretary | -- | -- | 1984 |
| Dr. Hong-Yu Wang Ph.D. | Chief Technology Officer | -- | -- | -- |
| Hongyan Sun | Deputy Director of Functional Pharmacodynamics Center | -- | -- | -- |
GemPharmatech Co., Ltd.
No. 12 Xuefu Road
Jiangbei New District
Nanjing, 210032
China
- Sector:
- Healthcare
- Industry: Biotechnology
Description
GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, disease mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides custom model generation, preclinical testing, germ-free and microbiome, cell lines and customization, custom breeding, animal quality testing, and other services. The company was founded in 2017 and is headquartered in Nanjing, China.
Corporate Governance
GemPharmatech Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
November 4, 2024 at 12:00 AM UTC
Ex-Dividend Date